Lipocalin-2 expression and function in pancreatic diseases

Kristyn Gumpper; Andrew William Dangel; Valentina Pita-Grisanti; Somashekar G. Krishna; Luis F. Lara; Thomas Mace; Georgios I. Papachristou; Darwin L. Conwell; Phil A. Hart; Zobeida Cruz-Monserrate

doi:10.1016/j.pan.2020.01.002

Lipocalin-2 expression and function in pancreatic diseases

Kristyn Gumpper, Andrew William Dangel, Valentina Pita-Grisanti, Somashekar G. Krishna, Luis F. Lara, Thomas Mace, Georgios I. Papachristou, Darwin L. Conwell, Phil A. Hart, Zobeida Cruz-Monserrate

Internal Medicine

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Lipocalin-2 (LCN2) is a secreted molecule, expressed in various cell types, that is involved in the progression of numerous diseases and disorders. The biological functions and expression levels of LCN2 in diseases including pancreatic cancer, pancreatitis (acute and chronic), and diabetes mellitus, suggest the potential role of LCN2 as a biomarker and/or therapeutic target. However, findings on the role of LCN2 in pancreatic diseases have been contradictory. In pancreatic cancer and pancreatitis, LCN2 has been identified as a potential biomarker; increased expression levels in various biological specimens correlate with the presence of the disease and may be able to differentiate cancer and chronic pancreatitis from healthy subjects. LCN2 is also known to be an adipokine; it is upregulated in obesity and is a common co-factor in the development of pancreatic diseases. Emerging research suggests LCN2 is elevated in type 2 diabetes mellitus, but the exact role of LCN2 in this disease is not clear. In this review, we summarize research on LCN2 as it relates to pancreatic diseases, highlighting the discrepancies in the literature. By explaining and clarifying the role of LCN2 in these disorders, we aim to promote research in developing novel diagnostic and treatment strategies to reduce the burden of pancreatic diseases.

Original language	English
Pages (from-to)	419-424
Number of pages	6
Journal	Pancreatology
Volume	20
Issue number	3
DOIs	https://doi.org/10.1016/j.pan.2020.01.002
State	Published - Apr 2020

Bibliographical note

Funding Information:
Research in this publication was supported by: The National Pancreas Foundation (ZC-M), The National Cancer Institute (NCI) R01CA223204 (ZC-M), and by the NCI and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under award number U01DK108327 (DC, ZC-M, PH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Funding Information:
Research in this publication was supported by: The National Pancreas Foundation (ZC-M), The National Cancer Institute (NCI) R01CA223204 (ZC-M), and by the NCI and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under award number U01DK108327 (DC, ZC-M, PH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Publisher Copyright:
© 2020 IAP and EPC

Keywords

Lipocalin-2
Neutrophil gelatinase-associated lipocalin
Obesity
Pancreatic cancer
Pancreatitis

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.pan.2020.01.002

Cite this

@article{2daef7aeae044507b7c0498a2a09128f,

title = "Lipocalin-2 expression and function in pancreatic diseases",

abstract = "Lipocalin-2 (LCN2) is a secreted molecule, expressed in various cell types, that is involved in the progression of numerous diseases and disorders. The biological functions and expression levels of LCN2 in diseases including pancreatic cancer, pancreatitis (acute and chronic), and diabetes mellitus, suggest the potential role of LCN2 as a biomarker and/or therapeutic target. However, findings on the role of LCN2 in pancreatic diseases have been contradictory. In pancreatic cancer and pancreatitis, LCN2 has been identified as a potential biomarker; increased expression levels in various biological specimens correlate with the presence of the disease and may be able to differentiate cancer and chronic pancreatitis from healthy subjects. LCN2 is also known to be an adipokine; it is upregulated in obesity and is a common co-factor in the development of pancreatic diseases. Emerging research suggests LCN2 is elevated in type 2 diabetes mellitus, but the exact role of LCN2 in this disease is not clear. In this review, we summarize research on LCN2 as it relates to pancreatic diseases, highlighting the discrepancies in the literature. By explaining and clarifying the role of LCN2 in these disorders, we aim to promote research in developing novel diagnostic and treatment strategies to reduce the burden of pancreatic diseases.",

keywords = "Lipocalin-2, Neutrophil gelatinase-associated lipocalin, Obesity, Pancreatic cancer, Pancreatitis",

author = "Kristyn Gumpper and Dangel, {Andrew William} and Valentina Pita-Grisanti and Krishna, {Somashekar G.} and Lara, {Luis F.} and Thomas Mace and Papachristou, {Georgios I.} and Conwell, {Darwin L.} and Hart, {Phil A.} and Zobeida Cruz-Monserrate",

note = "Funding Information: Research in this publication was supported by: The National Pancreas Foundation (ZC-M), The National Cancer Institute (NCI) R01CA223204 (ZC-M), and by the NCI and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under award number U01DK108327 (DC, ZC-M, PH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: Research in this publication was supported by: The National Pancreas Foundation (ZC-M), The National Cancer Institute (NCI) R01CA223204 (ZC-M), and by the NCI and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under award number U01DK108327 (DC, ZC-M, PH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2020 IAP and EPC",

year = "2020",

month = apr,

doi = "10.1016/j.pan.2020.01.002",

language = "English",

volume = "20",

pages = "419--424",

journal = "Pancreatology",

issn = "1424-3903",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Lipocalin-2 expression and function in pancreatic diseases

AU - Gumpper, Kristyn

AU - Dangel, Andrew William

AU - Pita-Grisanti, Valentina

AU - Krishna, Somashekar G.

AU - Lara, Luis F.

AU - Mace, Thomas

AU - Papachristou, Georgios I.

AU - Conwell, Darwin L.

AU - Hart, Phil A.

AU - Cruz-Monserrate, Zobeida

N1 - Funding Information: Research in this publication was supported by: The National Pancreas Foundation (ZC-M), The National Cancer Institute (NCI) R01CA223204 (ZC-M), and by the NCI and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under award number U01DK108327 (DC, ZC-M, PH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: Research in this publication was supported by: The National Pancreas Foundation (ZC-M), The National Cancer Institute (NCI) R01CA223204 (ZC-M), and by the NCI and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under award number U01DK108327 (DC, ZC-M, PH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: © 2020 IAP and EPC

PY - 2020/4

Y1 - 2020/4

N2 - Lipocalin-2 (LCN2) is a secreted molecule, expressed in various cell types, that is involved in the progression of numerous diseases and disorders. The biological functions and expression levels of LCN2 in diseases including pancreatic cancer, pancreatitis (acute and chronic), and diabetes mellitus, suggest the potential role of LCN2 as a biomarker and/or therapeutic target. However, findings on the role of LCN2 in pancreatic diseases have been contradictory. In pancreatic cancer and pancreatitis, LCN2 has been identified as a potential biomarker; increased expression levels in various biological specimens correlate with the presence of the disease and may be able to differentiate cancer and chronic pancreatitis from healthy subjects. LCN2 is also known to be an adipokine; it is upregulated in obesity and is a common co-factor in the development of pancreatic diseases. Emerging research suggests LCN2 is elevated in type 2 diabetes mellitus, but the exact role of LCN2 in this disease is not clear. In this review, we summarize research on LCN2 as it relates to pancreatic diseases, highlighting the discrepancies in the literature. By explaining and clarifying the role of LCN2 in these disorders, we aim to promote research in developing novel diagnostic and treatment strategies to reduce the burden of pancreatic diseases.

AB - Lipocalin-2 (LCN2) is a secreted molecule, expressed in various cell types, that is involved in the progression of numerous diseases and disorders. The biological functions and expression levels of LCN2 in diseases including pancreatic cancer, pancreatitis (acute and chronic), and diabetes mellitus, suggest the potential role of LCN2 as a biomarker and/or therapeutic target. However, findings on the role of LCN2 in pancreatic diseases have been contradictory. In pancreatic cancer and pancreatitis, LCN2 has been identified as a potential biomarker; increased expression levels in various biological specimens correlate with the presence of the disease and may be able to differentiate cancer and chronic pancreatitis from healthy subjects. LCN2 is also known to be an adipokine; it is upregulated in obesity and is a common co-factor in the development of pancreatic diseases. Emerging research suggests LCN2 is elevated in type 2 diabetes mellitus, but the exact role of LCN2 in this disease is not clear. In this review, we summarize research on LCN2 as it relates to pancreatic diseases, highlighting the discrepancies in the literature. By explaining and clarifying the role of LCN2 in these disorders, we aim to promote research in developing novel diagnostic and treatment strategies to reduce the burden of pancreatic diseases.

KW - Lipocalin-2

KW - Neutrophil gelatinase-associated lipocalin

KW - Obesity

KW - Pancreatic cancer

KW - Pancreatitis

UR - http://www.scopus.com/inward/record.url?scp=85077704701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077704701&partnerID=8YFLogxK

U2 - 10.1016/j.pan.2020.01.002

DO - 10.1016/j.pan.2020.01.002

M3 - Review article

C2 - 31932215

AN - SCOPUS:85077704701

SN - 1424-3903

VL - 20

SP - 419

EP - 424

JO - Pancreatology

JF - Pancreatology

IS - 3

ER -

Lipocalin-2 expression and function in pancreatic diseases

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this